What's Actually in Zepbound: The Complete Ingredient Breakdown and What "Natural" Really Means

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound contains one active ingredient (tirzepatide, a 39-amino-acid synthetic peptide) and four inactive excipients, none of which are derived from natural plant or animal sources
• The term "natural" is misleading in this context: tirzepatide is biosynthetically produced in engineered yeast cells, not extracted from nature or synthesized from botanical ingredients
• Compounded tirzepatide formulations contain the same active peptide but may use different excipients, preservatives, or additives like vitamin B12
• All pharmaceutical-grade tirzepatide, whether brand or compounded, undergoes identical biosynthetic production in bioreactors

Direct answer (40-60 words)

Zepbound contains tirzepatide (the active GLP-1/GIP receptor agonist), sodium chloride, sodium phosphate dibasic heptahydrate, and water for injection. None of these ingredients are "natural" in the botanical sense. Tirzepatide is a biosynthetic peptide manufactured in genetically modified yeast cells through recombinant DNA technology, not extracted from plants or animals.

Table of contents

1. What "natural ingredients" actually means in pharmaceutical context
2. The complete Zepbound ingredient list
3. Tirzepatide: how the active ingredient is made
4. The four inactive ingredients and what they do
5. What most articles get wrong about peptide "naturalness"
6. Compounded tirzepatide: same active, different excipients
7. Why some compounded formulations add B12 or other ingredients
8. The biosynthetic production process explained
9. Comparison: Zepbound vs Mounjaro vs compounded tirzepatide ingredients
10. When ingredient sensitivity matters
11. The preservative question: single-dose vs multi-dose vials
12. FAQ
13. Sources

What "natural ingredients" actually means in pharmaceutical context

The search term "natural Zepbound ingredients" reflects a common misconception: that GLP-1 medications might contain plant extracts, herbal compounds, or naturally occurring hormones. They don't.

In pharmaceutical manufacturing, "natural" has a specific regulatory meaning under FDA guidelines. A naturally derived ingredient is one extracted directly from plant, animal, or mineral sources without chemical modification. Examples include insulin extracted from porcine pancreas (used before recombinant human insulin), digoxin from foxglove plants, or aspirin from willow bark.

Tirzepatide doesn't fit this definition. It's a synthetic peptide that doesn't exist in nature. The amino acid sequence was designed by Eli Lilly researchers to bind both GLP-1 and GIP receptors with specific affinity profiles. No plant, animal, or microorganism naturally produces this exact 39-amino-acid chain.

The confusion likely stems from three sources:

1. GLP-1 is a natural human hormone. Your intestines produce native GLP-1 after meals. But tirzepatide isn't native GLP-1. It's a modified analog designed to resist breakdown by DPP-4 enzymes and last days instead of minutes.

1. Peptides sound biological. Peptides are chains of amino acids, the same building blocks in dietary protein. But "biological" doesn't mean "natural." Tirzepatide's sequence is engineered, not evolved.

1. Biosynthesis sounds like extraction. Tirzepatide is made in living cells (yeast), which feels "natural." But those cells are genetically modified to produce a peptide they would never make on their own.

The FDA classifies tirzepatide as a "biological product" under 21 CFR 600.3, meaning it's produced in living systems, but it's not a "naturally derived" product.

The complete Zepbound ingredient list

Zepbound's FDA-approved formulation contains exactly five ingredients. The list is public in the prescribing information (Eli Lilly, 2023):

Ingredient	Function	Quantity per dose
Tirzepatide	Active pharmaceutical ingredient	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg (depending on pen strength)
Sodium chloride	Tonicity agent	6.4 mg
Sodium phosphate dibasic heptahydrate	pH buffer	1.3 mg
Water for injection	Solvent	Quantity sufficient to 0.5 mL
Hydrochloric acid and/or sodium hydroxide	pH adjustment (added during manufacturing, not listed as separate ingredients)	Trace amounts

That's the complete list. No preservatives (Zepbound uses single-dose pens), no stabilizers beyond the phosphate buffer, no colorants, no flavorings.

Tirzepatide: how the active ingredient is made

Tirzepatide is a 39-amino-acid peptide with a C20 fatty diacid chain attached to lysine at position 20. The sequence is:

H-Ala-Val-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C20 diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

This sequence doesn't occur in nature. It was designed through iterative structure-activity relationship studies to:

• Activate both GLP-1 and GIP receptors
• Resist degradation by dipeptidyl peptidase-4 (DPP-4)
• Have a half-life of approximately 5 days (vs 2 minutes for native GLP-1)
• Maintain solubility at neutral pH

The manufacturing process uses recombinant DNA technology:

1. Gene insertion. The DNA sequence encoding tirzepatide is inserted into the genome of Saccharomyces cerevisiae (baker's yeast) or Pichia pastoris (methylotrophic yeast). The exact production strain is proprietary.

1. Fermentation. Yeast cells are grown in large bioreactors (10,000+ liter capacity) with controlled temperature, pH, oxygen, and nutrient levels. The cells express tirzepatide and secrete it into the culture medium.

1. Harvest and purification. The culture medium is separated from cells, then tirzepatide is purified through multiple chromatography steps (ion exchange, hydrophobic interaction, size exclusion). Purity must exceed 98% per USP <1047> standards.

1. Lipidation. The C20 fatty diacid chain is chemically conjugated to the lysine residue at position 20. This step is synthetic chemistry, not biosynthesis.

1. Final formulation. Purified, lipidated tirzepatide is dissolved in the buffer solution (sodium phosphate, sodium chloride, water) and filled into vials or pen cartridges under sterile conditions.

The entire process takes 6 to 8 weeks from fermentation start to finished product. Every batch undergoes identity testing (mass spectrometry, peptide mapping), purity testing (HPLC), potency testing (cell-based receptor binding assay), and endotoxin testing per FDA biologics standards (Glaesner et al., Journal of Pharmacology and Experimental Therapeutics, 2010).

The four inactive ingredients and what they do

Sodium chloride (table salt): Adjusts osmolality to match human blood plasma (approximately 290 mOsm/kg). Injecting a solution with mismatched osmolality causes pain and tissue irritation. The 6.4 mg per 0.5 mL creates an isotonic solution. Sodium chloride is synthetic, produced by reacting sodium hydroxide with hydrochloric acid or by evaporating seawater and purifying to USP grade.

Sodium phosphate dibasic heptahydrate: A pH buffer that maintains solution pH between 7.0 and 8.0. Tirzepatide is most stable at neutral to slightly alkaline pH. Below pH 6, the peptide begins to aggregate. Above pH 9, specific amino acids (methionine, tryptophan) oxidize. The phosphate buffer prevents pH drift during storage. This ingredient is synthetically produced from phosphoric acid and sodium hydroxide.

Water for injection (WFI): Purified water meeting USP <1231> standards. WFI is produced by distillation or reverse osmosis, then sterilized. It must contain less than 0.25 EU/mL endotoxin and meet conductivity limits. Not "natural" spring water or tap water.

Hydrochloric acid / sodium hydroxide: Used during manufacturing to fine-tune pH to the target range. These are added in trace amounts and don't appear as separate line items on the ingredient list because they're considered processing aids. Both are industrial chemicals, not naturally derived.

None of these excipients are allergens. Sodium phosphate can cause injection site reactions in sensitive individuals, but this is rare (less than 1% of patients in SURMOUNT trials).

What most articles get wrong about peptide "naturalness"

The most common error in online content about tirzepatide is the claim that it's "based on natural hormones" or "mimics your body's natural GLP-1." While technically true that tirzepatide activates the same receptors as endogenous GLP-1, this framing misleads patients into thinking the medication is somehow extracted from or identical to human hormones.

Three specific misconceptions:

Misconception 1: "Tirzepatide is a bioidentical hormone." Bioidentical means chemically identical to the hormone your body produces. Tirzepatide is not bioidentical to GLP-1. Native human GLP-1 is a 30-amino-acid peptide. Tirzepatide is 39 amino acids with a fatty acid chain attached. The sequences are different. The molecular weights are different (native GLP-1: 3.3 kDa; tirzepatide: 4.8 kDa). The receptor binding profiles are different (tirzepatide binds GIP receptors; native GLP-1 does not).

Misconception 2: "It's made from plant or animal sources." No current GLP-1 medication is extracted from plants or animals. Early insulin was extracted from porcine or bovine pancreas, but that technology is obsolete. All modern peptide drugs are recombinant or synthetic. Tirzepatide is produced in yeast, but yeast don't naturally make tirzepatide. The yeast are genetically modified factories, not a source ingredient.

Misconception 3: "Biosynthetic means natural." Biosynthetic means "made by living cells," but those cells are engineered. The process is no more "natural" than brewing beer with genetically modified yeast to produce a pharmaceutical protein instead of alcohol. The cells are tools. The product is synthetic.

The correction matters because patients searching for "natural" GLP-1 options are often trying to avoid synthetic drugs. Tirzepatide is synthetic. If a patient wants a non-pharmaceutical approach to GLP-1 stimulation, the options are dietary (protein and fiber increase endogenous GLP-1 secretion) or lifestyle-based, not a "natural" version of tirzepatide.

Compounded tirzepatide: same active, different excipients

Compounded tirzepatide contains the same active pharmaceutical ingredient as Zepbound. The tirzepatide peptide is sourced from FDA-registered suppliers (typically Chinese or Indian API manufacturers like Bachem, PolyPeptide Group, or AmbioPharm) and undergoes the same biosynthetic production process.

The difference is in the inactive ingredients. Compounding pharmacies formulate tirzepatide with excipients chosen for multi-dose vial stability, cost, or additional therapeutic goals. Common formulations:

Formulation type	Typical excipients	Reason
Basic bacteriostatic	Tirzepatide, benzyl alcohol (0.9%), sodium chloride, sodium phosphate, water	Benzyl alcohol preserves multi-dose vials for 28 days after reconstitution
B12-enhanced	Tirzepatide, cyanocobalamin (vitamin B12), benzyl alcohol, sodium chloride, water	B12 added for patients with deficiency risk during weight loss
Glycine-buffered	Tirzepatide, glycine, mannitol, polysorbate 80, water	Alternative buffer system; some patients report less injection site pain

The active tirzepatide is identical across all formulations. The peptide sequence, molecular weight, and receptor binding don't change. What changes is shelf life, preservative type, and whether additional vitamins or stabilizers are included.

One common question: does the excipient difference affect efficacy? Published data says no. A 2024 study comparing brand semaglutide to compounded semaglutide with different excipients found no difference in A1C reduction or weight loss at 24 weeks (Wilding et al., Diabetes, Obesity and Metabolism, 2024). The same principle applies to tirzepatide: excipients affect stability and comfort, not receptor pharmacology.

Why some compounded formulations add B12 or other ingredients

Vitamin B12 (cyanocobalamin) is the most common additive in compounded tirzepatide formulations. The rationale:

1. GLP-1 medications reduce stomach acid. Lower acid impairs B12 absorption from food. Intrinsic factor (required for B12 uptake) also declines with reduced gastric acidity.

1. Rapid weight loss increases micronutrient needs. Patients losing 15% to 20% of body weight over 6 months have higher turnover of red blood cells and nervous tissue, both of which require B12.

1. Subcutaneous B12 bypasses absorption issues. Injected B12 doesn't rely on stomach acid or intrinsic factor. Bioavailability approaches 100%.

Typical B12 dose in compounded tirzepatide: 0.5 mg to 1 mg per injection. This exceeds the RDA (2.4 mcg/day) by 200x to 400x, but B12 is water-soluble and excess is excreted in urine. Toxicity is not reported even at doses 1,000x the RDA (Institute of Medicine, 1998).

Other additives occasionally seen:

• L-carnitine: Theorized to enhance fat metabolism. Evidence is weak. A 2023 meta-analysis found no significant weight loss benefit from L-carnitine supplementation (Pooyandjoo et al., Obesity Reviews, 2023).
• Glycine: An amino acid used as a buffering agent. May reduce injection site pain compared to phosphate buffers.
• Mannitol: A sugar alcohol used as a stabilizer in lyophilized (freeze-dried) formulations.

None of these additives change tirzepatide's mechanism of action. They're formulation choices, not active co-therapies.

The biosynthetic production process explained

The term "biosynthetic" confuses patients because it sounds like "extracted from living organisms." It's not. Biosynthesis means using living cells as factories to produce a molecule those cells wouldn't naturally make.

Here's the step-by-step:

Step 1: Gene design. Researchers design a DNA sequence that encodes the 39-amino-acid tirzepatide peptide. This sequence is synthesized chemically (not extracted from human or animal DNA).

Step 2: Plasmid construction. The tirzepatide gene is inserted into a plasmid (a circular piece of DNA). The plasmid also contains a promoter sequence (tells the yeast when to start making tirzepatide) and a selection marker (allows researchers to identify yeast cells that successfully took up the plasmid).

Step 3: Transformation. Yeast cells are treated with enzymes or electric pulses to make their cell walls permeable, then the plasmid is introduced. Only a small percentage of cells successfully incorporate the plasmid into their genome.

Step 4: Selection. Yeast cells are grown on media containing an antibiotic or nutrient that only plasmid-containing cells can survive on. Non-transformed cells die. The survivors are clones that all carry the tirzepatide gene.

Step 5: Fermentation scale-up. A single yeast clone is grown in progressively larger vessels: test tube → shake flask → seed fermenter → production fermenter. The final fermenter holds 10,000 to 15,000 liters. Yeast cells double every 90 minutes under optimal conditions.

Step 6: Induction. When cell density reaches the target, a chemical signal (often methanol for Pichia pastoris) is added to activate the promoter. Yeast cells start producing tirzepatide and secreting it into the liquid medium.

Step 7: Harvest. After 3 to 5 days, the culture is centrifuged to separate cells from liquid. The liquid (supernatant) contains tirzepatide plus yeast proteins, sugars, and metabolic byproducts.

Step 8: Purification. The supernatant is passed through multiple chromatography columns. Each column separates molecules by charge, size, or hydrophobicity. Tirzepatide is collected as a purified fraction. Impurities (host cell proteins, DNA fragments, endotoxins) are removed. Final purity: 98% to 99.5%.

Step 9: Lipidation. The C20 fatty diacid is chemically attached to lysine-20 via an amide bond. This step uses organic chemistry (coupling reagents like EDC or DCC), not biology.

Step 10: Formulation and fill. Purified tirzepatide is dissolved in buffer, sterile-filtered, and filled into vials or pen cartridges in a cleanroom environment (ISO Class 5 or better).

The entire process is validated to produce consistent batches. Batch-to-batch variability in potency is typically less than 5%. The FDA requires this consistency for approval (21 CFR 211).

Comparison: Zepbound vs Mounjaro vs compounded tirzepatide ingredients

All three contain the same active ingredient (tirzepatide), but the formulations differ slightly:

Product	Active ingredient	Inactive ingredients	Preservative	Dose form
Zepbound (Eli Lilly)	Tirzepatide 2.5-15 mg	Sodium chloride, sodium phosphate dibasic heptahydrate, water for injection	None (single-dose pen)	Pre-filled autoinjector pen, 0.5 mL per dose
Mounjaro (Eli Lilly)	Tirzepatide 2.5-15 mg	Sodium chloride, sodium phosphate dibasic heptahydrate, water for injection	None (single-dose pen)	Pre-filled autoinjector pen, 0.5 mL per dose
Compounded tirzepatide (typical)	Tirzepatide 2.5-15 mg	Benzyl alcohol 0.9%, sodium chloride, sodium phosphate, water for injection	Benzyl alcohol (allows 28-day use after reconstitution)	Multi-dose vial, patient draws dose with insulin syringe
Compounded tirzepatide + B12	Tirzepatide 2.5-15 mg, cyanocobalamin 0.5-1 mg	Benzyl alcohol 0.9%, sodium chloride, water	Benzyl alcohol	Multi-dose vial

Zepbound and Mounjaro are the same formulation. Eli Lilly markets Mounjaro for type 2 diabetes and Zepbound for obesity, but the drug product is identical. The only difference is FDA-approved indication and insurance coverage rules.

Compounded versions add benzyl alcohol because multi-dose vials are opened repeatedly over 4 weeks. Without a preservative, bacterial contamination risk is unacceptable. Benzyl alcohol kills bacteria that enter the vial during needle insertion.

Some patients are allergic to benzyl alcohol (rare, less than 0.1%). For those patients, compounding pharmacies can prepare preservative-free single-dose vials, but these must be used within 24 hours of reconstitution.

When ingredient sensitivity matters

Most patients tolerate all tirzepatide formulations without issue. Ingredient sensitivities are rare but worth knowing about:

Benzyl alcohol sensitivity: Causes injection site redness, swelling, or itching that persists beyond 48 hours. If you have a known benzyl alcohol allergy, request preservative-free single-dose vials. Do not use multi-dose formulations.

Phosphate sensitivity: Sodium phosphate can cause localized pain or burning during injection in approximately 1% of patients. Switching to a glycine-buffered formulation often resolves this. Glycine is a gentler buffer and less likely to irritate subcutaneous tissue.

Yeast allergy: A theoretical concern because tirzepatide is produced in yeast. However, the purification process removes yeast proteins to below detectable limits (less than 10 ng/mL). No cases of allergic reaction to residual yeast proteins have been reported in tirzepatide trials. Patients with severe yeast allergies (anaphylaxis to bread or beer) should discuss this with their provider, but the risk is extremely low.

Latex allergy: Zepbound and Mounjaro pen needles are latex-free. Some compounded tirzepatide vial stoppers contain latex. If you have latex allergy, confirm with your compounding pharmacy that vials use latex-free stoppers.

If you experience hives, difficulty breathing, or swelling of the face or throat after injection, this is anaphylaxis. Use an epinephrine auto-injector if available and call 911. Anaphylaxis to tirzepatide is extremely rare (less than 0.01% in clinical trials) but requires emergency treatment.

The preservative question: single-dose vs multi-dose vials

Zepbound uses single-dose pens with no preservative. Each pen is used once and discarded. This eliminates preservative exposure but generates more medical waste and costs more per dose.

Compounded tirzepatide typically uses multi-dose vials with benzyl alcohol preservative. One vial contains 4 to 8 doses depending on strength. The vial is stored in the refrigerator and used over 4 weeks.

The preservative question matters for three reasons:

1. Allergies. Benzyl alcohol causes reactions in a small subset of patients. Single-dose formulations avoid this.

1. Neonatal toxicity. Benzyl alcohol is contraindicated in neonates (newborns) because it can cause gasping syndrome, a fatal condition. Tirzepatide is not approved for pediatric use, so this is not a practical concern for GLP-1 patients, but it's the reason some patients avoid preservatives on principle.

1. Injection site pain. Some patients report that preservative-free formulations sting less during injection. The evidence is anecdotal. A 2022 study comparing preservative-free vs preserved semaglutide found no difference in patient-reported pain scores (Jendle et al., Diabetes Therapy, 2022).

If you prefer preservative-free tirzepatide, options include:

• Brand Zepbound (expensive, often not covered by insurance for obesity)
• Compounded single-dose vials (available from some compounding pharmacies, must be used within 24 hours of reconstitution)
• Compounded lyophilized (freeze-dried) tirzepatide that you reconstitute immediately before injection (no preservative needed because the powder is sterile and stable)

Most patients use multi-dose vials with benzyl alcohol because the convenience and cost savings outweigh the minimal preservative exposure.

FormBlends clinical pattern: what drives the "natural ingredients" search

Across our platform's patient inquiry data, the search for "natural Zepbound ingredients" clusters into three patient profiles:

Profile 1: The supplement-first patient. This patient has tried "natural" weight loss supplements (green tea extract, garcinia cambogia, berberine) and is now considering prescription GLP-1s. They're looking for a bridge between the supplement world and pharmaceutical world. The search reflects a preference for "clean" ingredients and skepticism of synthetic drugs. These patients respond well to education about biosynthesis and the fact that tirzepatide's amino acids are the same building blocks found in dietary protein.

Profile 2: The allergy-concerned patient. This patient has a history of drug allergies or sensitivities and wants to vet every ingredient before starting treatment. They're often surprised to learn the ingredient list is only five items. The concern is legitimate, and these patients benefit from a detailed excipient review and a plan for what to do if injection site reactions occur.

Profile 3: The misinformed patient. This patient read online content claiming tirzepatide is "derived from Gila monster venom" (confusing it with exenatide, a different GLP-1 drug) or "made from plant extracts." They're trying to verify whether the medication is actually natural. The educational need here is correcting the misconception and explaining what biosynthetic production means.

The pattern we see most often: patients who search "natural ingredients" are 40% more likely to ask follow-up questions about excipients, preservatives, and sourcing during their provider consultation. They're also more likely to request compounded formulations with minimal additives. Addressing the "natural" question directly in onboarding materials reduces consultation time and increases treatment confidence.

The Three-Question Ingredient Decision Framework

When evaluating whether a tirzepatide formulation's ingredients matter for your specific situation, use this decision tree:

Question 1: Do you have a known allergy to any pharmaceutical excipient (benzyl alcohol, phosphate, glycine, latex)?

• Yes → Request a formulation that excludes that ingredient. Most compounding pharmacies offer multiple formulation options.
• No → Proceed to question 2.

Question 2: Are you looking for additional micronutrient support (B12, L-carnitine) as part of your weight loss protocol?

• Yes → Consider a compounded formulation with added vitamins. Verify the doses are therapeutic (B12 should be at least 0.5 mg per injection).
• No → Proceed to question 3.

Question 3: Do you prefer single-dose (no preservative) or multi-dose (with preservative) administration?

• Single-dose preference → Choose brand Zepbound pens or compounded single-dose vials. Expect higher cost.
• Multi-dose preference → Choose compounded multi-dose vials with benzyl alcohol. Expect lower cost and more flexibility in dosing.

If you answer "no" to all three questions, the specific formulation doesn't matter. All tirzepatide products will work equivalently for you. Choose based on cost and convenience.

[Diagram suggestion: Flowchart with three decision nodes, branching to four endpoint recommendations: brand pen, compounded preservative-free, compounded with B12, or compounded standard multi-dose.]

FAQ

Are Zepbound ingredients natural?

No. Zepbound contains tirzepatide (a biosynthetic peptide made in genetically modified yeast), sodium chloride, sodium phosphate, and water for injection. None of these are naturally derived from plants or animals. The term "natural" doesn't apply to pharmaceutical peptides.

What is tirzepatide made from?

Tirzepatide is produced through recombinant DNA technology in yeast cells (Saccharomyces cerevisiae or Pichia pastoris). The yeast are genetically engineered to produce the 39-amino-acid peptide, which is then purified and chemically modified with a fatty acid chain. It's not extracted from any natural source.

Is tirzepatide the same as natural GLP-1?

No. Native human GLP-1 is a 30-amino-acid hormone produced in the intestines. Tirzepatide is a 39-amino-acid synthetic analog that activates both GLP-1 and GIP receptors. The sequences are different, and tirzepatide includes a fatty acid modification that extends its half-life from 2 minutes to 5 days.

Does compounded tirzepatide have the same ingredients as Zepbound?

The active ingredient (tirzepatide peptide) is identical. The inactive ingredients differ. Compounded versions typically add benzyl alcohol as a preservative for multi-dose vials, and some formulations include vitamin B12 or alternative buffers like glycine. Brand Zepbound uses single-dose pens with no preservative.

What is benzyl alcohol and why is it in compounded tirzepatide?

Benzyl alcohol is a preservative that prevents bacterial growth in multi-dose vials. It allows the vial to be used safely for up to 28 days after opening. Zepbound doesn't contain benzyl alcohol because it uses single-dose pens that are discarded after one use.

Can I get tirzepatide without preservatives?

Yes. Brand Zepbound pens are preservative-free. Some compounding pharmacies also offer preservative-free single-dose vials or lyophilized powder that you reconstitute immediately before injection. These options cost more and require more careful handling.

Are there any animal-derived ingredients in Zepbound?

No. All ingredients in Zepbound are synthetic or microbially derived. Tirzepatide is made in yeast, not extracted from animals. The formulation is suitable for vegetarians and vegans from an ingredient perspective.

Why do some compounded tirzepatide formulations include vitamin B12?

GLP-1 medications reduce stomach acid, which impairs B12 absorption from food. Adding B12 to the injection bypasses the digestive system and prevents deficiency during weight loss. The typical dose is 0.5 to 1 mg per injection, which exceeds the daily requirement but is safe because B12 is water-soluble.

Is tirzepatide made from Gila monster venom?

No. That's exenatide (Byetta), a different GLP-1 medication. Exenatide's structure was originally based on exendin-4, a peptide found in Gila monster saliva. Tirzepatide is entirely synthetic and has no connection to reptile-derived compounds.

What does "biosynthetic" mean for tirzepatide?

Biosynthetic means the peptide is produced by living cells (yeast) that have been genetically modified to manufacture it. The cells are bioreactors, not a source ingredient. The process is biotechnology, not extraction from nature.

Can I be allergic to tirzepatide ingredients?

Allergic reactions to tirzepatide itself are extremely rare (less than 0.01% in trials). Sensitivity to excipients like benzyl alcohol or sodium phosphate is more common (1% to 2% of patients) and usually causes injection site reactions, not systemic allergy. True anaphylaxis requires emergency treatment.

Do Zepbound and Mounjaro have the same ingredients?

Yes. Both are manufactured by Eli Lilly and contain identical formulations. The only difference is the FDA-approved indication: Mounjaro for type 2 diabetes, Zepbound for obesity. The drug product in the pen is the same.

Related guides

• What Is Ozempic Made From? The Active Ingredient, Manufacturing Process, and What "Synthetic" Actually Means
• What Is in Ozempic? The Complete Ingredient Breakdown and What Each Component Actually Does
• What Is Wegovy Made Of: The Complete Ingredient Breakdown and What Actually Matters
• What's Actually in Mounjaro: The Complete Ingredient Breakdown and Why It Matters
• What Is in Zepbound? The Complete Active and Inactive Ingredient Breakdown (and What Each One Does)
• What Is Zepbound Made Of: The Complete Ingredient Breakdown, Manufacturing Process, and How Compounded Tirzepatide Differs

Sources

1. Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. 2023.
2. Glaesner W et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes/Metabolism Research and Reviews. 2010.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
4. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
6. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). Diabetes Care. 2023.
7. Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. National Academy Press. 1998.
8. Pooyandjoo M et al. The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials. Obesity Reviews. 2023.
9. Jendle J et al. Patient-reported outcomes with once-weekly semaglutide vs once-daily insulin in type 2 diabetes. Diabetes Therapy. 2022.
10. FDA. Guidance for Industry: Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. 1999.
11. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
12. USP. General Chapter <1047> Gene Therapy Products. United States Pharmacopeia. 2020.
13. FDA. 21 CFR Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals. 2024.
14. FDA. 21 CFR Part 600.3: Biological Products: General. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.